Clinical Trials in Manchester, England
1 recruiting
Showing 1–7 of 7 trials
Recruiting
Phase 2
A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.
Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations
Taiho Oncology, Inc.220 enrolled80 locationsNCT05967689
Recruiting
Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
OSE Immunotherapeutics363 enrolled207 locationsNCT06472245
Recruiting
Phase 1
Study of XB010 in Subjects With Solid Tumors
Locally Advanced or Metastatic Solid TumorsNSCLC (Non-small Cell Lung Cancer)Esophageal Squamous Cell Cancer+1 more
Exelixis396 enrolled17 locationsNCT06545331
Recruiting
Phase 3
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Lung CancerEGFRNSCLC, Stage IB-IIIA+5 more
Taiho Oncology, Inc.360 enrolled214 locationsNCT07128199
Recruiting
Phase 2
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Metastatic Non Small Cell Lung Cancer
Iovance Biotherapeutics, Inc.170 enrolled84 locationsNCT04614103
Recruiting
Phase 2
PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer
Breast Neoplasm
Institute of Cancer Research, United Kingdom119 enrolled6 locationsNCT03740893
Recruiting
Phase 1Phase 2
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
Solid Tumors
ORIC Pharmaceuticals350 enrolled42 locationsNCT05315700